

ResMed Announces FDA Clearance of iVAPS Therapy Mode for Astral Life Support Ventilators

New addition allows clinicians to utilize a Volume-Assured Pressure Support mode on Astral in all of its circuit configurations

SAN DIEGO – June 1, 2016 – ResMed today announced U.S. Food and Drug Administration (FDA) clearance of the iVAPS (intelligent Volume-Assured Pressure Support) therapy mode for its Astral™ life support ventilators.

ResMed's award-winning, cloud-connected Astral ventilators are used for a range of respiratory conditions including chronic obstructive pulmonary disease (COPD), neuromuscular disease and restrictive thoracic disorder.

iVAPS intelligently and automatically adapts to patients' changing needs by constantly monitoring their actual ventilation and respiratory rate in relation to their target ventilation and respiratory rate, and automatically adjusting pressure support as needed to accommodate each patient's unique needs, even as their disease progresses.

"The iVAPS therapy mode has been one of the most requested enhancements to the platform," said Luke Maguire, president of ResMed's Cardio-Respiratory Care Global Business Unit. "Its introduction dramatically increases Astral's capabilities and gives pulmonologists, home medical equipment (HME) providers and others more flexibility."

ResMed IntelligentAir suite

iVAPS is one of two key technologies within ResMed's IntelligentAir suite in the United States. The other is Intelligent Backup Rate (iBR), which provides backup breaths only when needed to give patients a chance to spontaneously trigger the ventilator.

Ease of Use

Adding iVAPS in Astral allows clinicians to now utilize ResMed's best-in-class masks, such as the AirFit™ Series, with a volume-assured mode of ventilation. This will improve the level of care our providers deliver while allowing them to utilize the full breadth of ResMed mask options.

Availability

The iVAPS therapy mode is scheduled to be available for Astral in the U.S. in June 2016. It was previously launched for use in Europe in 2015. Providers seeking more information on adding the mode to their existing Astral device should contact their ResMed sales representative.

About Astral

Introduced in 2014, ResMed's Astral life support ventilators offer unparalleled mobility and ease of use for patients suffering from neuromuscular disease, COPD, and other adult and pediatric breathing disorders. Astral 100 and Astral 150 life support ventilators offer the best battery-to-weight ratio on the market with an eight-hour internal battery and a weight of only 7.1 pounds.

About ResMed

ResMed changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, COPD and other chronic diseases. ResMed is a global leader in connected care, with more than 1 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.

ResMed.com | [Facebook](#) | [Twitter](#) | [LinkedIn](#)

<https://newsroom.resmed.com/2016-06-01-ResMed-Announces-FDA-Clearance-of-iVAPS-Therapy-Mode-for-Astral-Life-Support-Ventilators>